Cequent Pharmaceuticals said this week that Steven Tregay has been appointed to the company’s board of directors.
Tregay is a managing director of the Novartis Option Fund, a $200 million equity-investment fund operated by the Novartis Corporate Venture Funds. He joined Cequent’s board following an undisclosed investment in the company by the Novartis Option Fund (see related story, this issue).
Tregay has held several different roles with Novartis, and holds a PhD and MS in organic chemistry from Harvard University.